Successful Integrations, Growth Brands, and Pipeline Innovations Boost Revenue Growth - Research Report on Johnson & Johnson, Abbott, St. Jude Medical, Lilly, and Novartis

NEW YORK, July 22, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Abbott Laboratories (NYSE: ABT), St. Jude Medical, Inc. (NYSE: STJ), Eli Lilly & Co. (NYSE: LLY), and Novartis AG, Inc. (NYSE: NVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On July 16, 2013, Johnson & Johnson reported its Q2 2013 financial results. Sales increased 8.5% YoY to $17.9 billion. Sales included the contribution from its recent acquisition of Synthes, Inc. The Company stated that excluding this impact, global operational sales growth stood at 5.6% YoY. Net earnings were $3.8 billion or $1.33 per diluted share, as compared to $1.4 billion or $0.50 per diluted share in Q2 2012. Commenting on the results, Alex Gorsky, Chairman and CEO, said, "Our strong second-quarter results reflect the progress we've made against our near-term priorities of delivering on our financial commitments, restoring a reliable supply of over-the-counter products to consumers, continuing the successful integration of Synthes and building on the momentum in our pharmaceutical business. Our talented colleagues at Johnson & Johnson continue to bring meaningful innovations to patients and consumers around the world and have positioned us well to deliver sustainable growth." For full-year FY 2013, the Company expects earnings of $5.40 to $5.47 per diluted share. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/07a8_JNJ]

Abbott Laboratories Research Report

On July 17, 2013, Abbott Laboratories (Abbott) reported its financial results for Q2 2013. Total sales increased by 2.5% YoY to $5.4 billion. According to the Company, sales were driven by 8.4% operational sales growth in Nutrition, including 18.4% international growth, and 7.6% operational sales growth in Diagnostics. Miles D. White, Chairman and CEO of Abbott, said, "All things considered, including headwinds from foreign exchange and a mixed global economy, this was a good quarter ." For full-year FY 2013, the Company expects ongoing EPS to be in the range of $1.98 to $2.04 and GAAP EPS from continuing operations to be in the range of $1.39 to $1.45 per diluted share. The Full Research Report on Abbott Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/05c1_ABT]

St. Jude Medical, Inc. Research Report

On July 17, 2013, St. Jude Medical, Inc. (St. Jude Medical) reported Q2 2013 financial results. Net sales fell marginally by 0.5% YoY to $1.4 billion. According to the Company, unfavorable currency translation comparisons decreased sales by approximately $31 million. On a neutral currency basis, net sales increased 2% YoY. Adjusted net earnings were $275 million or $0.96 per share as compared to adjusted net earnings of $276 or $0.88 per share in Q2 2012. Daniel J. Starks, Chairman, President, and CEO, of St. Jude Medical, said, "During the second quarter, St. Jude Medical made good progress towards accelerating our sales growth on a sustainable basis. Our operating discipline, healthy balance sheet and strong cash flow will continue to allow us to fund disciplined acquisitions and return value to shareholders. We remain confident in our ability to deliver double-digit constant currency growth in 2013 adjusted earnings per share." For Q3 2013 and full-year FY 2013, the Company expects consolidated net earnings within the range of $0.88 to $0.90 per share and $3.70 to $3.73 per share, respectively. The Full Research Report on St. Jude Medical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/b338_STJ]

Eli Lilly & Co. Research Report

On July 16, 2013, Eli Lilly & Co. (Lilly) announced that study results published in the Journal of Sexual Medicine showed a greater percentage of men who had an incomplete response to as-needed PDE5 inhibitor treatment returned to normal erectile function when given Cialis once daily, compared to placebo, as measured by the erectile function domain of the International Index of Erectile Function (IIEF-EF). Furthermore, the Company revealed that in a pre-specified secondary measure, Cialis significantly improved erectile function scores versus placebo in those men who had an incomplete response to as-needed PDE5 treatment. Cialis is indicated for the treatment of men with erectile dysfunction (ED), men with the signs and symptoms of benign prostatic hyperplasia (BPH, and men with both ED and symptoms of BPH. The drug is approved by the Food and Drug Administration (FDA). The Full Research Report on Eli Lilly & Co. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/977d_LLY]

Novartis AG, Inc. Research Report

On July 17, 2013, Novartis AG, Inc. (Novartis) reported its Q2 2013 financial results. Group net sales increased 1% YoY to $14.5 billion. Net income stood at $2.6 billion or $1.03 per diluted share, as compared to $2.7 billion or $1.09 per diluted share in Q2 2012. Joseph Jimenez, CEO of Novartis, said, "Successful execution on growth brands allowed us to navigate patent expiries and new competition, while deepening our footprint in Emerging Growth Markets like China and Russia." The Full Research Report on Novartis AG, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/9b6d_NVS]

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

www.analystscorner.com

SOURCE Analysts' Corner